Original Research

Sustained biochemical control in patients with acromegaly treated with lanreotide depot 120 mg administered every 4 weeks, or an extended dosing interval of 6 or 8 weeks: a pharmacokinetic approach

Gomez-Panzani E, Chang S, Ramis J, Landolfi MM, Bakker B

Research and Reports in Endocrine Disorders 2012, 2:79-84

Published Date: 14 December 2012